Register to get unlimited Level 2

Company Announcements

Changes to interests of a significant shareholder

Related Companies

By LSE RNS

RNS Number : 2102J
Alliance Pharma PLC
26 June 2017
 

For immediate release

26 June 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Changes to interests of a significant shareholder

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder.   In accordance with AIM rule 17, the following details are now notified:

 

(a)  Identity of the significant shareholder: Mr Nigel Wray

(b)  Date of disclosure: 26 June 2017

(c)   Date of relevant change: 23 June 2017

(d)  Price, amount and class: 8,000,000 ordinary shares of 1p each; price not disclosed

(e)  Nature of transaction: sale of shares

(f)   Nature and extent of significant shareholder's interest: direct and indirect interests

(g)  Resultant shareholding: 1.59% (direct) and 1.59% (indirect) = 3.18% total

 

In compliance with DTR5, a copy of the notification received from this investor is appended.

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Andrew Franklin, Chief Financial Officer

 

Rob Bellhouse, Company Secretary

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles

 

 

 

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

 

Corporate Broking: James Black / Toby Adcock

 

 

Notes to editors:

 

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii

ALLIANCE PHARMA PLC     

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to the
notification obligation: iii

NIGEL WRAY     

4. Full name of shareholder(s)
 (if different from 3.):iv

UBS PRIVATE BANKING NOMINEES LTD

 

ROY NOMINEES LIMITED  

5. Date of the transaction and date on
which the threshold is crossed or
reached: v

23 June 2017

6. Date on which issuer notified:

26 June 2017 

7. Threshold(s) that is/are crossed or
reached: vi, vii

3%
         
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares GB0031030819

23,092,593

 

23,092,593

7,551,269

7,551,269

7,541,324

1.59%

1.59%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

15,092,593

 

3.18%
                                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees

7,551,269 held by UBS Private Banking Nominees Ltd

The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited   - 7,541,324

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A

 


13. Additional information:

 

Figures are based on a total number of voting

         rights of 474,307,589

 

14. Contact name:

Nigel Wray

15. Contact telephone number:

020 7647 7647
     

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGUQPQUPMGQQ

Top of Page